Telehealth

When Manufacturers Sell Direct: LillyDirect, Vials and the New Price Floor

Lilly sells Zepbound vials direct through LillyDirect, and Novo now sells Wegovy at a flat cash price. Independent clinics that once filled the access gap need a value story beyond access.

The new price floor
On this pageJump to a section

$349. $499. $499.

Those are three price tags from two manufacturers in about a week, and together they redefine what a patient sees when they search for GLP-1 treatment online. If you run an independent telehealth clinic, the comparison your patient makes just changed, and you need a value story beyond access.

I am not a lawyer, and this is not legal advice. Prices below are as announced by the dates cited and may have changed.

What did the manufacturers announce?

Here is the sequence, in order.

LillyDirect, January 2024

Lilly introduced LillyDirect on January 4, 2024 as a digital healthcare experience offering disease education, a digital pharmacy for select Lilly medicines with home delivery through third-party pharmacy services, and access to independent telehealth providers.1 That last item matters to you. The independent providers on the site make their own treatment decisions.

Self-pay vials, August 2024

On August 27, 2024 Lilly said Zepbound 2.5 mg and 5 mg single-dose vials were available for self-pay to patients with an on-label prescription. A four-week supply of the 2.5 mg dose was $399 and the 5 mg dose was $549. Lilly described a multi-step verification process so the vials are dispensed only to patients with a valid on-label electronic prescription from their provider.2

A price cut, February 2025

On February 25, 2025, according to CNBC, Lilly lowered the 2.5 mg vial to $349 and the 5 mg vial to $499, and added 7.5 mg and 10 mg vials at $499 for a first fill and any refill within 45 days of the previous delivery, otherwise $599 and $699. Patients draw up the medicine themselves with a syringe and needle, and the 12.5 mg and 15 mg doses are not offered in vials.3

$349

Lilly's price for a month of Zepbound 2.5 mg vials via LillyDirect, after the February 25, 2025 cut (CNBC)Source 3
ChartUS dollarsLilly Zepbound vial prices after the February 25, 2025 cut
Lilly Zepbound vial prices after the February 25, 2025 cut
LabelValue
2.5 mg$349
5 mg$499
7.5 mg (first fill or refill within 45 days)$499
10 mg (first fill or refill within 45 days)$499
7.5 mg (otherwise)$599
10 mg (otherwise)$699

Source: CNBC (via NBC DFW), Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access

NovoCare Pharmacy, March 2025

On March 5, 2025 Novo Nordisk announced NovoCare Pharmacy, offering all strengths of Wegovy at $499 per month to cash-paying patients, with direct-to-home shipping fulfilled by CenterWell Pharmacy. It said eligible patients include the uninsured and commercially insured people without obesity-medicine coverage.4

$499

Novo Nordisk's monthly cash price for all Wegovy doses through NovoCare Pharmacy, announced March 5, 2025Source 4

Why does a manufacturer price floor matter to independent clinics?

Because a patient can now see a branded price directly from the maker, and any clinic offer is judged against it.

Access used to be the product

When supply was short and options were limited, a clinic that could get a patient on treatment fast was selling something scarce. That advantage was already shrinking after the semaglutide shortage ended, and it shrinks further when the manufacturer sells direct at a clear published price. Access becomes the baseline, not the pitch.

The patient's comparison is changing

The patient does not think about 503A versus 503B or about shortage lists. They see a number. If your page does not explain why your total cost includes something worth paying for, you lose to the simplest comparison on the screen.

Provide a more affordable solution.

Patrik Jonsson, Eli Lilly (as reported by CNBC)Source 3

Where the manufacturer channel has limits

Read the fine print the way a patient would. Per CNBC, Lilly's vials are for patients diagnosed by a health care provider with obesity, or obesity with obstructive sleep apnea. Patients draw up the medicine with a needle and syringe, and the highest two doses are not sold in vials.3 Lilly's August release stresses that vials go only to patients with an on-label prescription.2

None of that is a criticism. It is a map of where a patient may still need a clinician: to evaluate eligibility, to teach and support the injection routine, and to adjust the plan when the first few weeks do not go as hoped, the stall point I covered in GLP-1 patient retention.

What can an independent clinic offer that a pharmacy channel does not?

The care around the medication. Not as a slogan, as a specific, deliverable service.

Manufacturer channel (pharmacy and price)What an independent clinic can add
A published price for the medicationA clinician who evaluates the patient and owns the plan
Home deliveryFollow-up that fits the patient's life
Support materials for self-injectionSide effect support and dose guidance from a clinician
A prescription from a provider of the patient's choiceNutrition, strength and habit coaching
Verification that the prescription is on-labelMonitoring, labs and results tracking

Zach Reitano, the CEO of telehealth company Ro, has been pushing the same idea for a while. In a CNBC interview posted on June 4, 2024, he said:

You'll see GLP-1s serve as the sun around which all other care will orbit.

Zach Reitano, CNBC TelevisionSource 5Watch at 3:03

He runs a company that sells care around these drugs, so he is talking his book. I still agree with half of it. The medication is the hook, and the care around it is the part an independent clinic can own.

VideoCNBC Television

Ro CEO Zach Reitano talks new GLP-1 supply tracker

In the same interview he notes Lilly was getting approved single-dose vials, the product that became its self-pay vials later that year.

Watch on YouTube (opens in a new tab)

Clinical evaluation and continuity

Lilly's own release says vials are for patients with a valid prescription from the health care provider of their choice.2 Somebody has to be that provider, evaluate the patient, and stay with them. That is a service, and it can be excellent or forgettable.

The experience around the shot

Most patients do not fail because the medicine is unavailable. They stall because of side effects, plateaus, confusion about dosing, or loss of motivation. A clinic that responds quickly to those moments is selling something a pharmacy cannot.

How should a patient compare you? Help them do it.

Show the total, not the fragment. If your monthly price includes the evaluation, the medication, the follow-up and the support, say what each part is. If the medication is bought separately through a manufacturer channel, show that cost beside your program fee so the patient sees a real total.

A simple way to show it

  • What the patient pays you each month, and what it covers.
  • What the medication costs, and who supplies it.
  • What happens when something goes wrong, such as a side effect or a missed week.
  • How to reach a human, and how fast.

Transparent totals build trust and blunt the "why is this more than the drug price?" objection before it is asked.

How should you reposition your offer?

  1. List what you deliver today, in clinical and service terms, not marketing terms.
  2. Decide which parts patients would miss if they bought the drug elsewhere. That is your real value.
  3. Rewrite your page to lead with the care model and the outcomes tracking you can show.
  4. Price the program clearly. Separate your fee from the medication cost where that applies.
  5. Retrain your team to answer the price comparison honestly and calmly.
  6. Review your claims with counsel and clinicians before relaunching.

What does this mean for your marketing?

I come at this as someone who buys traffic for a living, so here is the plain version. When a patient can see a clear branded price from the maker, ads that win on price alone get expensive and thin, and the claim limits in what clinics can and cannot claim still apply. The ads and pages that hold up lead with who the patient will work with, what the first 90 days look like and how follow-up works.

Sell the care around the drug. The drug is now visible to everyone. The care is the part you control. If you want to see how I build care-first funnels for clinics, start at my telehealth page.

Keep building.Ekai

Questions people ask

What is LillyDirect?

LillyDirect is Eli Lilly's digital healthcare experience, launched January 4, 2024. It offers disease information, home delivery of select Lilly medicines through third-party pharmacy services, and access to independent telehealth providers.

How much do Zepbound vials cost through LillyDirect?

As of Lilly's February 25, 2025 update, as reported by CNBC, the 2.5 mg vial was $349 and the 5 mg vial $499 per month. The 7.5 mg and 10 mg vials were $499 for a first fill and any refill within 45 days of the previous delivery, otherwise $599 and $699.

What is NovoCare Pharmacy?

Novo Nordisk announced NovoCare Pharmacy on March 5, 2025, offering all doses of FDA-approved Wegovy at $499 per month for cash-paying patients, with home delivery fulfilled by CenterWell Pharmacy.

How can an independent telehealth clinic compete with manufacturer pricing?

Not on drug price alone. Independent clinics can compete on the quality of care around the medication: clinical evaluation, monitoring, follow-up, side effect support, behavior and nutrition guidance, and clear total pricing.

Sources

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Video: Ro CEO Zach Reitano talks new GLP-1 supply tracker

    CNBC TelevisionYouTube, Jun 4, 2024

  • lillydirect
  • zepbound vials
  • novocare pharmacy
  • telehealth pricing
  • glp-1 telehealth
Ekai Stone

Ekai Stone

17 years in business for myself. 12 years running Meta ads, since 2014. Ad director for three 8 figure brands and one 9 figure brand. I build revenue systems that owners keep and run.

ekaistone.comResultsThe Seven Star Build

Read next, from the archive

Related reading

More in Telehealth

Disclaimer. Results shared on this site are from real clients and reflect years of experience, proven systems, high ad spend, and efficient work. They are not guarantees of income or performance. Every business is different and your results will depend on your offer, effort, decisions, and commitment. Marketing involves risk. If you're looking for shortcuts, this isn’t for you.

Not Facebook™. This site is not a part of the Facebook™ website or Facebook Inc. Additionally, This site is NOT endorsed by Facebook™ in any way. FACEBOOK™ is a trademark of FACEBOOK™, Inc.